1,2-Dimethylcyclopentan-1-amine | 89854-73-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,2-Dimethylcyclopentan-1-amine
• CAS: 89854-73-9
• 化学式: C₇H₁₅N
• 分子量: 113.2
• InChiKey: YRRPKYQXTRFWID-UHFFFAOYSA-N

物化性质

• 沸点：
  135 °C
• 密度：
  0.840±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：SHANGHAI BLUERAY BIOPHARMA CO., LTD.

  公开号：US20210053989A1

  公开（公告）日：2021-02-25

  Disclosed in the present disclosure are a pyrimidine-fused cyclic compound or a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer, solvate or isotope labeled compound thereof. Also provided in the present disclosure are a preparation method for the compound, a composition comprising the compound and a use of the compound for the preparation of a medicament for the prevention and/or treatment of a disease or condition associated with abnormal SHP2 activity.

  本公开涉及一种嘧啶融合的环状化合物或其药用可接受的盐、水合物、前药、立体异构体、溶剂合物或同位素标记化合物。本公开还提供了该化合物的制备方法、包含该化合物的组合物以及该化合物用于制备与异常SHP2活性相关的疾病或病况的药物的用途。
• [EN] SOLVENTS<br/>[FR] SOLVANTS
  申请人：BIONIQS LTD

  公开号：WO2009034329A1

  公开（公告）日：2009-03-19

  There is described the use of a protic ionic liquid comprising a trialkylammonium salt as a solvent.

  这里描述了一种包含三烷基铵盐的质子离子液体作为溶剂的使用。
• [EN] 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS<br/>[FR] DÉRIVÉS DE 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHÉNYL)-URÉE UTILISÉS COMME INHIBITEURS DE CXCR2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015181186A1

  公开（公告）日：2015-12-03

  The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

  这项发明涉及1-(3-磺酰基苯基)-3-(环戊-2-烯-1-基)脲衍生物，以及它们在治疗或预防由CXCR2受体介导的疾病和症状中的应用。此外，该发明涉及含有这些衍生物的组合物和它们的制备方法。
• NOVEL COMPOUNDS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20150232460A1

  公开（公告）日：2015-08-20

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, R a , R b , R 1 , R 2 and R 3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了公式(I)的化合物及其药用盐，其中L、X、Ra、Rb、R1、R2和R3如规范中定义，以及其制备方法、含有它们的药物组合物以及它们在治疗中的用途。
• Preparation of 2-alkyl-3-(4,5-dihydroisoxazol-3-yl) halobenzenes
  申请人：——

  公开号：US20020156290A1

  公开（公告）日：2002-10-24

  A novel process for preparing the compounds of the formula I 1 where: n is 0, 1 or 2; R 1 ,R 2 are C 1 -C 6 -alkyl; R 3 ,R 4 ,R 5 are hydrogen or C 1 -C 6 -alkyl, or R 4 and R 5 together form a bond; R 6 is Cl, Br, which comprises a synthesis sequence starting from 1,2-dialkylbenzenes of the formula II 2 with subsequent halogenation to give 3,6-dihalo-1,2-dialkylbenzenes, haloalkylation to give benzyl bromides, oxidation to give benzaldehydes, oximation, reaction 40 with alkenes to give isoxazoles, conversion into thioethers and, if appropriate, oxidation to give sulfenyl or sulfonyl derivatives of the formula I.

  一种用于制备化合物I1的新工艺，其中：n为0、1或2；R1、R2为C1-C6烷基；R3、R4、R5为氢或C1-C6烷基，或者R4和R5共同形成键；R6为Cl、Br，包括从式II2的1,2-二烷基苯开始的合成序列，随后进行卤代反应得到3,6-二卤代-1,2-二烷基苯，卤代烷基化得到苄溴化物，氧化得到苯甲醛，氧化反应生成异噁唑烷，转化为硫醚，如有必要，氧化得到式I的砜基或磺酰基衍生物。